Tag Archives: alpha-L-fucosidase

Alpha-L-fucosidase as a putative prognostic biomarker in breast cancer

12.06.2024   Uncategorized   No comments

Z. M. A. A. Hamodat1*, H. H. Abdulwahhab2, A. R. M. T. Hamodat3

1Department of Chemistry, College of Science, University of Mosul, Iraq;
2Northern Technical University, AL-dour, Iraq;
3Mosul Center for Cardiac Medicine and Surgery, Mosul, Iraq;
*e-mail: zahraahamodat@uomosul.edu.iq

Received: 05 January 2024; Revised: 03 February 2024;
Accepted: 31 May 2024; Available on-line: 17 June 2024

Search for reliable biomarkers for predicting progression of breast cancer is essential in managing the disease. So, we are trying to provide new insights into the potential role of alpha-fucosidase (AFU) as a putative prognostic biomarker in breast cancer as compared to classic markers. The study included 56 women with breast cancer; 25 had early breast cancer, and the rest (31) had metastatic breast cancer. Thirty healthy women were considered a control group. Early breast cancer patients had a significantly increased (P ≤ 0.0001) AFU level compared with the control group. A non-significant difference in the De-ritis ratio appeared for early breast cancer compared with control. Metastatic breast cancer had a significantly (P ≤ 0.0001) increased AFU and De-ritis ratio compared with early breast cancer and the control group. A positive significant (P = 0.01) correlation exists between AFU level, age factor (r = 0.295), and the De-ritis ratio in breast cancer patients. We can conclude that it is possible to consider alpha-L-fucosidase (AFU) as a putative prognostic biomarker in breast cancer more potent than the ratio of De-Ritis. Moreover, the coincidence of elevated AFU and De-ritis levels in metastatic breast cancer gives us an idea of the stage of the disease.

Read More

Properties of alpha-L-fucosidase for serum of patients with hepatocellular cancer and cytotoxicity on some cancer cell lines

16.12.2021   Uncategorized   No comments

Z. M. A. A. Hamodat

University of Mosul, College of Science, Chemistry Department, Mosul – Iraq;
e-mail: zahraahamodat@uomosul.edu.iq

Received: 07 July 2021; Accepted: 12 November 2021

Alpha-L-fucosidase (FUCA) degrades many fucosylated glycans and has long been recognized as a tumor marker associated with the early detection of some cancers. This study aimed to purify and characterize alpha-L-fucosidase from the serum of patients with hepatocellular cancer and estimate its toxic effect against hepatocellular carcinoma HepG2, prostate cancer PC3 cell lines and the standard hepatocyte WRL-68 cell line. SDS-Page Electrophoresis technique was used to determine the purity of the purified alpha-L fucosidase and estimate its molecular weight. Three purification steps were used for FUCA purification: precipitation with 65% ammonium sulfate saturation, DEAE-cellulose ion exchange, Sephadex G-75 gel filtration. The procedure resulted in 54% recovery of the enzyme with 27.5-fold purification and 14 U/mg specific activity. It was demonstrated that FUCA purified from the serum of HCC patients showed a more toxic effect on HepG2 cells (IC50 of 65.74 µg/ml) than on PC3 prostate cancer cells (IC50 of 111.5 g/ml) and less toxic effect against standard hepatocyte WRL-68cells (IC50 of 214.5 µg/ml). We can conclude that the inhibitory effect of the purified FUCA on hepatocellular carcinoma is more than its effect on prostate cancer cells. Also, the purified FUCA may be used in studies on anticancer drug development in liver cancer.

Read More